Sudden death in hypertrophic cardiomyopathy;Muerte súbita en la miocardiopatía hipertrófica

Revista Espanola de Cardiologia

Volumn 51, Issue 12, 1998, Pages 991-996

  Brugada, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Hypertrophic cardiomyopathy; Sudden death

Indexed keywords

MYOSIN HEAVY CHAIN;

ADOLESCENT; ADULT; AGE; CHILD; DEFIBRILLATOR; GENETICS; HEART STROKE VOLUME; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORTALITY; MUTATION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SUDDEN DEATH;

ADOLESCENT; ADULT; AGE FACTORS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MUTATION; MYOSIN HEAVY CHAINS; RISK FACTORS; STROKE VOLUME; TACHYCARDIA, VENTRICULAR;

EID: 0032240842     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(98)74853-5     Document Type: Review

References (33)

1. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979; 43: 1.242-1.244.
2. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7: 204-214.
3. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O-Doneghue A et al. The role of cardiac troponin T and alfa tropomyosin mutations in hypertrophic cardiomyopathy. N Engl J Med 1995; 332: 1.058-1.064.
4. Watkins H, Rosenzweig A, Huang DS, Levi T, McKenna WJ, Seidman CE et al Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1.108-1.114.
5. Maron BJ, Lipson LC, Roberts WC, Savage DD, Epstein SE. Malignant hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978; 41: 1.133-1.140.
6. Spirito P, Seidman CE, McKenna WJ, Maron BJ. Management of hypertrophic cardiomyopathy. N Engl J Med 1997; 30: 775-785.
7. McKenna WJ, Deanfield JE, Faroqui A, England D, Oakley C, Goodwin JF. Prognosis in hypertrophic cardiomyopathy role of age and clinical electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-538.
8. Maron BJ, Savage DD, Wolfson JK, Epstein SE, Prognostic significance of 24-hour ambulatory monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981; 48: 252-257.
9. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993; 72: 970-972.
10. Kofflard MJ, Waldstein DJ, Vos J, Ten Cate FJ. Prognosis in hypertrophic cardiomyopathy: a retrospective study. Am J Cardiol 1993; 72: 939-943.
11. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92: 1.680-1.692.
12. Hecht GM, Panza JA, Maron BJ. Clinical course of middle-aged asymptomatic patients with hypertrophic cardiomyopathy, Am J Cardiol 1992; 69: 935-940.
13. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA 1996; 276: 199-204.
14. Maron BJ, Kogan J, Proschan MA, Hecht GM, Roberts WC. Circadian variation in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1994; 23. 1.405-1.409.
15. Von Dohlen TW, Prisant LM, Frank MJ. Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy. Am J Cardiol 1989, 64: 498-503
16. McKenna WJ, Chetty S, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48-hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980; 45. 1-5.
17. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia is a frequent cause of cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. Circulation 1990; 82: 35A.
18. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984, 59: 971-975.
19. Romeo F, Cianfrocca C, Pelliccia F, Colloridi V, Cristofane R, Reale A. Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than or equal to 14 years at diagnosis. Clin Cardiol 1990; 13: 101-107.
20. Fananapazir L, McAreavey D, Epstein ND. Hypertrophic cardiomyopathy. En: Zipes DP, Jalife J, editores. Cardiac electrophysiology: from cell to bedside. Filadelfia: WB Saunders, 1995; 769-779
21. Maron BJ, Roberts WC, Epstein SE Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982; 65: 1.388-1.394.
22. Chang AC, McAreavey D, Fananapazir L. Identification of patients with hypertrophic cardiomyopathy at high risk for sudden death. Curr Opin Cardiol 1995; 10: 9-15.
23. Mulrow JP, Healy MJ, McKenna WJ. Variability of ventricular arrhythmias in hypertrophic cardiomyopathy and implications for treatment. Am J Cardiol 1986; 58: 615-618.
24. Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO, Bonow RO et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80: 1.259-1.268.
25. Kuck KH, Kunze KP, Schlüter M, Nienaber CA, Costard A. Programmed stimulation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J 1988; 9: 177-185.
26. Fananapazir L, Epstein SE. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. Am J Cardiol 1991; 67: 175-182
27. Watson RM, Schwartz JL, Maron BJ, Tucker E, Rosing DR, Josephson ME. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy and high risk for sudden death. J Am Coll Cardiol 1987; 10: 761-774.
28. Kowey PR, Eisenberg R, Engel TR. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy. N Engl J Med 1984; 310: 1.566-1.569.
29. Marian AJ. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin Cardiol 1995; 18: 189-198.
30. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1.085-1.086.
31. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-416.
32. Fananapazir L, Leon MB, Bonow RO. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991; 67: 169-174.
33. Primo J, Geelen P, Brugada J, Lorga A, Mont L, Wellens F et al. Hypertrophic cardiomyopathy: role of the implantable defibrillator. J Am Coll Cardiol 1998. En prensa.